

## CONTENTS

# Web Exclusive: Clinical Trials for CUP

A listing of clinical trials for patients with cancers of unknown primary are listed below.

**Therapy:** Treatment based on molecular profiling assay – paclitaxel, carboplatin, bevacizumab, erlotinib

**Cancer:** Carcinoma of Unknown Primary

**Phase:** II

**Sponsor/Manufacturer:** Sarah Cannon Research Institute/Genentech

**Contact information:** John D. Hainsworth, MD, 615-329-7274;

[jhainsworth@tnonc.com](mailto:jhainsworth@tnonc.com)

**Therapy:** Avastin (bevacizumab)

**Cancer:** Neuroendocrine Carcinoma

**Phase:** III

**Sponsor/Manufacturer:** Southwest Oncology Group, National Cancer Institute

**Contact information:** James Yao, MD, 713-792-2828; [jyao@mdanderson.org](mailto:jyao@mdanderson.org) or 800-392-1611

**Therapy:** Taxotere (docetaxel), 5-FU (5-fluorouracil), Platinol (cisplatin)

**Cancer:** Squamous Cell or Undifferentiated Carcinoma

**Phase:** II

**Sponsor/Manufacturer:** M.D. Anderson Cancer Center/Sanofi-Aventis

**Contact information:** Ehab Y. Hanna, MD, 713-745-2672;

[eyhanna@mdanderson.org](mailto:eyhanna@mdanderson.org)

**Therapy:** Xeloda (capecitabine)

**Cancer:** Solid Tumors and Adenocarcinoma of Unknown Primary

**Phase:** I/II

**Sponsor/Manufacturer:** Ohio State University Comprehensive Cancer Center

**Contact information:** OSU Cancer Clinical Trial Matching Service – 866-627-7616; [osu@emergingmed.com](mailto:osu@emergingmed.com)

**Therapy:** Vectibix (panitumumab)

**Cancer:** Squamous Cell Carcinoma of the Head and Neck; Undifferentiated Carcinoma; Adenosquamous Cell Carcinoma

**Phase: I**

**Sponsor/Manufacturer:** Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital/Amgen

**Contact information:** Lori J. Wirth, MD, 617-632-3090; [lwirth@partners.org](mailto:lwirth@partners.org)

**Therapy:** Nexavar (sorafenib)

**Cancer:** Advanced Solid Tumors

**Phase: II**

**Sponsor/Manufacturer:** University of California Davis

**Contact information:** UC Davis Clinical Trials Office – 916-734-3089 or Primo N. Lara, MD, 916-734-3772; [primo.lara@ucdmc.ucdavis.edu](mailto:primo.lara@ucdmc.ucdavis.edu)

**Therapy:** Stereotactic Body Radiotherapy

**Cancer:** Spinal Neoplasms

**Phase: I/II**

**Sponsor/Manufacturer:** M.D. Anderson Cancer Center

**Contact information:** Eric L. Chang, MD, 713-563-2300;  
[echang@mdanderson.org](mailto:echang@mdanderson.org)

*Investigators in clinical trials may be individual physicians, researchers at institutions, or pharmaceutical company representatives. The contact information given here was provided by those running these trials and was accurate at the time of publication. If you get a voice mail, leave the pertinent information. For additional trials, go to [www.curetoday.com/trialcheck](http://www.curetoday.com/trialcheck)*